VIVUS’s “Buy” Rating Reaffirmed at Bank of America Corp. (VVUS)
VIVUS (NASDAQ:VVUS)‘s stock had its “buy” rating reiterated by equities research analysts at Bank of America Corp. in a research note issued to investors on Wednesday, American Banking and Market News reports. They currently have a $17.00 target price on the stock. Bank of America Corp.’s target price would suggest a potential upside of 81.24% from the stock’s previous close.
A number of other firms have also recently commented on VVUS. Analysts at Piper Jaffray Cos. cut their price target on shares of VIVUS (NASDAQ:VVUS) from $20.00 to $14.00 in a research note to investors on Thursday, September 12th. They now have a “sell” rating on the stock. Separately, analysts at Lazard Capital Markets downgraded shares of VIVUS (NASDAQ:VVUS) from a “neutral” rating to a “sell” rating in a research note to investors on Wednesday, September 4th. They now have a $8.00 price target on the stock. Finally, analysts at JMP Securities downgraded shares of VIVUS (NASDAQ:VVUS) from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, September 3rd. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $14.70.
VIVUS (NASDAQ:VVUS) traded up 8.53% on Wednesday, hitting $10.1803. The stock had a trading volume of 1,385,249 shares. VIVUS has a 1-year low of $9.11 and a 1-year high of $23.59. The stock’s 50-day moving average is $11.19 and its 200-day moving average is $12.5. The company’s market cap is $1.027 billion.
VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.11. The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $12.76 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. On average, analysts predict that VIVUS will post $-1.97 earnings per share for the current fiscal year.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.